SAN FRANCISCO, Jan. 15, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) announced that Michael S. Weiss, the Company's Executive Chairman and Interim CEO, will present an update on the Company's development programs for TG-1101, the Company's novel anti-CD20 monoclonal antibody, and TGR-1202, the Company's novel PI3K delta inhibitor, as well as an overview of TG Therapeutics' corporate goals for 2015. The presentation will occur today, Thursday January 15th, at 8:30 am PT, during the 33rd Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, CA.
As part of the presentation, Mr. Weiss will outline the following corporate goals for 2015:
- Aggressively recruit into the GENUINE Phase 3 Clinical Trial of TG-1101 in combination with ibrutinib, which is now open for enrollment
- Commence additional combination Phase 3 clinical trials, particularly for the Company's proprietary combination of TG-1101 plus TGR-1202 in patients with Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)
- Commence clinical development for the Company's IRAK4 inhibitor program, expected in the second half of 2015
- Launch new triple therapy combination trials in addition to the currently enrolling Phase 1/2 trial of TG-1101 plus TGR-1202 plus ibrutinib
- Commence clinical development program for the treatment of autoimmune diseases across the Company's portfolio of development candidates
- Data update on Phase 1 and 2 clinical trials at major hematology/oncology conferences during 2015
"We remain focused on developing the most efficacious, least toxic treatment options for patients with B-cell malignancies, and it has long been our belief that the combination of multiple novel agents is the best way to achieve this goal," said Michael S. Weiss, the Company's Executive Chairman and Interim CEO. "For 2015, we plan to expand our registration program to include our first Phase 3 clinical trial for our proprietary combination of TG-1101 and TGR-1202 in CLL and in NHL. Furthering that effort, we will broaden our exploratory triple therapy combination trials to continue to push toward better outcomes and possibly cures. We enter 2015 with great optimism as we build TG into what we believe will be the leading company in the treatment of B-cell malignancies and diseases."
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors, also for B-cell malignancies and autoimmune diseases. TG Therapeutics is headquartered in New York City.
Some of the statements included in this press release, particularly those, with respect to anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101, TGR-1202 and the IRAK-4 inhibitor program may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101, TGR-1202 and the IRAK-4 inhibitor program; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101, TGR-1202 and the IRAK-4 inhibitor program will not be reproduced in additional patients or in future studies; the risk that trends observed which underlie certain assumptions of future performance of TGR-1202 will not continue, the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the completion of the current phase 1 study; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
TGTX - G
CONTACT: Jenna Bosco Director- Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: firstname.lastname@example.org
Source:TG Therapeutics, Inc.